BioCardia公司宣布,其针对缺血性心力衰竭的Cardiamp细胞疗法,已获得日本药品医疗器械综合机构(PMDA)的咨询记录支持,这为后续的正式法规提交与审批铺平了道路。
BioCardia公司宣布,其针对缺血性心力衰竭的Cardiamp细胞疗法,已获得日本药品医疗器械综合机构(PMDA)的咨询记录支持,这为后续的正式法规提交与审批铺平了道路。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.